Your SSCP Is Not a Summary—It’s a Clinical Argument
I reviewed an SSCP last month where the Executive Summary section ran longer than the actual clinical evaluation conclusions. The manufacturer had produced a 40-page document filled with device descriptions, detailed study protocols, and literature search methods. When the Notified Body asked where the benefit-risk analysis was documented, the answer was: “We thought that was the CER’s job.” That’s the problem. The Summary of Safety and Clinical Performance is treated like a condensed CER when it’s actually a standalone clinical argument designed for a different audience entirely.
In This Article
The SSCP is one of the most misunderstood documents under MDR. Manufacturers often see it as a regulatory formality, a summary to check off before submission. But reviewers read it differently. They see it as the final statement on whether your device is safe, whether it performs as intended, and whether the clinical evidence supports your claims in a format accessible to healthcare professionals and patients.
That difference in perspective creates most of the deficiencies I see.
What the MDR Actually Requires
Article 32 of MDR 2017/745 establishes the SSCP as a mandatory document for Class III and implantable devices. Annex XIV defines its structure in detail. This is not optional. It’s not a marketing document. It’s a clinical evidence summary that must be publicly available via Eudamed.
The regulation is explicit: the SSCP must present the clinical data in a way that is understandable to the intended user and, where applicable, to patients. That means you’re not writing for regulatory reviewers anymore. You’re writing for clinicians who need to make informed decisions about using your device.
This shift in audience is where manufacturers lose control of the narrative.
The SSCP is not an internal regulatory document. It’s a public-facing clinical argument that must defend your device’s benefit-risk profile to healthcare professionals and informed patients.
Structure Is Not Optional
Annex XIV lays out 15 mandatory sections. Every submission I review follows this structure—on paper. But following the headings doesn’t mean you’ve met the requirement. The regulation specifies what must be included under each heading, and that’s where most SSCPs collapse.
Let me walk through the sections that generate the most deficiencies.
Device Identification and Specifications
This section seems straightforward. Basic UDI. Device description. Intended purpose. But I see manufacturers copy-paste from the Instructions for Use without considering what a clinician actually needs to understand the device’s role in clinical practice.
The question is not just “what is the device?” but “how does this device fit into the clinical pathway?” If you’re submitting a cardiovascular stent, I need to understand the lesion types it addresses, the vessel diameters it’s designed for, and the procedural context. If that’s missing, the SSCP fails before the clinical data even appears.
Indications and Target Population
Here’s where clarity matters. The indication statement must match what’s in the CER, the IFU, and the labeling. Any inconsistency raises a flag. But beyond consistency, the target population must be described with enough precision that a clinician reading the SSCP can immediately assess whether the device is appropriate for their patient.
I’ve seen SSCPs state the indication as “for use in patients requiring cardiac pacing” without specifying whether this applies to permanent pacing, temporary pacing, single-chamber or dual-chamber systems, or specific arrhythmias. That level of vagueness makes the document unusable in clinical decision-making.
Indication statements that are too broad to guide clinical use. If a physician can’t determine from your SSCP whether the device applies to their patient, the document has failed its purpose.
Clinical Benefits and Performance
This is the core of the SSCP. It’s where you present the clinical evidence that supports your device’s claimed benefits. Not the studies themselves—the outcomes. Not the design of your pivotal trial—the results that matter to clinical practice.
Manufacturers often list endpoints without interpretation. “The primary endpoint was met with a p-value of 0.03.” That tells me nothing about clinical relevance. What I need is: “The device reduced major adverse cardiac events by 22% compared to the control group at 12 months, with a number needed to treat of 18.”
The performance claim must be supported by data, but more importantly, it must be contextualized. How does this compare to existing treatment options? What does this outcome mean for the patient’s quality of life? The SSCP is not a results table. It’s a clinical argument.
Residual Risks and Undesirable Side Effects
This section reveals how honestly a manufacturer understands their device. I see two extremes: SSCPs that list every theoretical risk from the risk management file, creating a wall of text that obscures real clinical concerns, and SSCPs that minimize known complications by hiding them in passive language.
The regulation requires transparency. If your device has a known complication rate—device thrombosis, infection, lead fracture—it must be stated clearly with the incidence rate from your clinical data. If there are residual risks that cannot be mitigated, they must be acknowledged and weighed against the clinical benefit.
Reviewers can detect evasion immediately. And so can clinicians.
A credible SSCP acknowledges risks with precision and supports the benefit-risk conclusion with data. Vague risk statements undermine the entire document’s credibility.
Alternative Treatment Options
This is the section manufacturers want to skip. But Annex XIV requires it. You must describe the alternative treatments or devices available for the same indication and, where possible, compare outcomes.
I understand the concern. Why draw attention to competing devices? Because the clinician reading your SSCP is already aware of those alternatives. If you don’t address them, you’ve left the comparison to the reader’s assumptions. That’s not a strong clinical argument.
The comparison doesn’t need to be exhaustive, but it must be fair. If your device offers a minimally invasive approach compared to open surgery, state that. If the alternative is medical management with known efficacy and safety data, acknowledge it. Then explain why your device adds clinical value.
The Executive Summary Problem
The Executive Summary is supposed to synthesize the entire SSCP in a way that a non-specialist can understand the device’s purpose, benefits, and risks. It’s the first thing a reader sees. It’s often the only thing a patient or general practitioner will read.
And yet, most Executive Summaries I review are written like regulatory abstracts. Dense clinical terminology. Complex statistical outcomes. No clear statement of what the device does or why it matters.
The test I use: if a general practitioner reads your Executive Summary, can they explain to a patient what this device is for and whether it’s appropriate? If not, the summary has failed.
Executive Summaries written for regulatory reviewers instead of healthcare professionals. The result is a document that meets the format requirement but fails the communication requirement.
How the SSCP Relates to the CER
Manufacturers often ask: isn’t this just repeating the CER? The answer is no, but I understand the confusion. Both documents present clinical evidence. Both must support the benefit-risk profile. But the purpose and audience are different.
The CER is a technical evaluation of all available clinical data. It’s written for regulators and Notified Bodies who need to assess whether the evidence is sufficient, whether gaps exist, and whether post-market surveillance is adequate. The CER digs into study quality, appraisal of equivalence, literature synthesis, and evidence gaps.
The SSCP is the conclusion of that evaluation, translated into clinically relevant terms. It assumes the evidence has been appraised. It presents the outcomes that matter to clinical decision-making. It addresses the benefit-risk balance in the context of available alternatives.
Think of it this way: the CER answers “is the evidence robust?” The SSCP answers “should a clinician use this device?”
What Happens When the SSCP Is Weak
A weak SSCP generates regulatory deficiencies, but the consequences go beyond the approval process. Because the SSCP is publicly available through Eudamed, it becomes part of the device’s clinical reputation. Clinicians will read it. Hospitals will reference it in purchasing decisions. Patients may review it during informed consent.
If the SSCP is vague on indications, unclear on benefits, or evasive on risks, that lack of clarity affects market perception. I’ve seen well-designed devices struggle commercially because their SSCP failed to communicate clinical value effectively.
The regulatory requirement is a minimum. The real standard is whether the document supports informed clinical decision-making.
Practical Steps to Strengthen Your SSCP
Start with the audience. Before writing a single section, define who will read this document and what decision they need to make. A cardiologist evaluating a new stent system needs different information than a hospital procurement committee assessing cost-effectiveness.
Write the Executive Summary last, not first. Once the full SSCP is complete, distill it into language a general practitioner can understand. Test it with someone outside your regulatory team.
Be precise with indications. If your device is intended for a specific patient population or clinical scenario, state it explicitly. Avoid broad claims that require the reader to infer applicability.
Present clinical benefits in terms that matter to practice. Don’t just report statistical significance. Explain what the outcome means for the patient. Use absolute risk reduction, number needed to treat, and clinically relevant thresholds.
Acknowledge risks honestly. If there’s a known complication, state the incidence and how it’s managed. If there’s a residual risk that can’t be eliminated, explain why the benefit justifies it.
Compare alternatives fairly. Don’t exaggerate your device’s advantages, but don’t ignore them either. A balanced comparison strengthens your clinical argument.
The strongest SSCPs are those written as if a critical clinician will challenge every claim. If your document can defend itself under that scrutiny, it will pass regulatory review and support clinical adoption.
Final Thought
The SSCP is not a summary. It’s a clinical argument that must stand on its own. It must convince a healthcare professional that your device offers a valid treatment option. It must inform a patient about what to expect. And it must do this in clear, precise, defensible language.
Most manufacturers treat it as a regulatory obligation. The ones who treat it as a clinical communication tool produce documents that pass review faster and support market success more effectively.
The question is not whether your SSCP meets Annex XIV’s structure. The question is whether it actually informs the clinical decision it was designed to support.
Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.
Frequently Asked Questions
What is a Clinical Evaluation Report (CER)?
A CER is a mandatory document under MDR 2017/745 that demonstrates the safety and performance of a medical device through systematic analysis of clinical data. It must be updated throughout the device lifecycle based on PMCF findings.
How often should the CER be updated?
The CER should be updated whenever significant new clinical data becomes available, after PMCF activities, when there are changes to the device or intended purpose, and at minimum during annual reviews as part of post-market surveillance.
What causes CER rejection by Notified Bodies?
Common reasons include inadequate equivalence demonstration, insufficient clinical data for claims, poorly structured SOTA analysis, missing gap analysis, and lack of clear benefit-risk determination. Structure and logical flow are as important as the data itself.
Which MDCG guidance documents are most relevant for clinical evaluation?
Key documents include MDCG 2020-5 (Equivalence), MDCG 2020-6 (Sufficient Clinical Evidence), MDCG 2020-13 (CEAR Template), MDCG 2020-7 (PMCF Plan), and MDCG 2020-8 (PMCF Evaluation Report).
Need Expert Help with Your Clinical Evaluation?
Get personalized guidance on MDR compliance, CER writing, and Notified Body preparation.
✌
Peace, Hatem
Your Clinical Evaluation Partner
Follow me for more insights and practical advice.
– MDR 2017/745 Article 32
– MDR 2017/745 Annex XIV
– MDCG 2019-9: Summary of Safety and Clinical Performance
